| Bioactivity | sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM. sRANKL-IN-2 can be used for the research of osteoporosis[1]. |
| Invitro | sRANKL-IN-2 (Compound S3-05) (0.03-10 μM; 24 h) induces mature osteoclasts apoptosis and attenuates bone resorption in a dose-dependent manner[1].sRANKL-IN-2 (0-10 μM; 14 days) increases cell proliferation and mineralization in mouse embryonic mesenchymal stem cell line C3H10T1/2 or human primary osteoblasts cells with osteogenic differentiation medium[1]. Apoptosis Analysis[1] Cell Line: |
| Name | sRANKL-IN-2 |
| CAS | 2411216-42-5 |
| Formula | C18H18N4O7S |
| Molar Mass | 434.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
sRANKL-IN-2
CAS: 2411216-42-5 F: C18H18N4O7S W: 434.42
sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.